Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iveson

Showing results (491-500 of 573) with videos related to

Pageof 58
Sort By:
European Journal of Cancer (Oxford, England : 1990)|July 20, 2005
Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancerIan Chau, Andrew R Norman, David Cunningham, et al.
Current Colorectal Cancer Reports|September 14, 2013
The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current StatusThierry André, Timothy Iveson, Roberto Labianca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 14, 2018
The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?A Sobrero, A Grothey, T Iveson, et al.
The New England Journal of Medicine|July 27, 2007
Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancerDavid J Kerr, Janet A Dunn, Michael J Langman, et al.
Inorganic Chemistry|January 16, 2003
Crystallographic, X-ray absorption, and IR studies of solid- and solution-state structures of tris(nitrato) N,N,N',N'-tetraethylmalonamide complexes of lanthanides. Comparison with the Americium complexC Den Auwer, M C Charbonnel, M G Drew, et al.
Cancer Chemotherapy and Pharmacology|February 4, 2014
Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trialCarlos R Becerra, Ramon Salazar, Rocio Garcia-Carbonero, et al.
World Journal of Gastroenterology|January 11, 2014
Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagusFergus Noble, Luke Nolan, Adrian C Bateman, et al.
British Journal of Cancer|June 9, 2026
Body mass index, adjuvant chemotherapy, toxicity, and survival in non-metastatic colorectal cancer: an individual participant data meta-analysis (OCTOPUS)Corinna G V Slawinski, Lee Malcomson, Jorge Barriuso, et al.
Wellcome Open Research|September 14, 2020
Using a knowledge exchange event to assess study participants' attitudes to research in a rapidly evolving research contextIona Beange, Elizabeth J Kirkham, Sue Fletcher-Watson, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|July 23, 2020
Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysisPhilip H Pucher, Saqib A Rahman, Robert C Walker, et al.
Pageof 58

Showing results (491-500 of 573) with videos related to

Sort By:
Pageof 58
European Journal of Cancer (Oxford, England : 1990)|July 20, 2005
Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancerIan Chau, Andrew R Norman, David Cunningham, et al.
Current Colorectal Cancer Reports|September 14, 2013
The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current StatusThierry André, Timothy Iveson, Roberto Labianca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 14, 2018
The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?A Sobrero, A Grothey, T Iveson, et al.
The New England Journal of Medicine|July 27, 2007
Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancerDavid J Kerr, Janet A Dunn, Michael J Langman, et al.
Inorganic Chemistry|January 16, 2003
Crystallographic, X-ray absorption, and IR studies of solid- and solution-state structures of tris(nitrato) N,N,N',N'-tetraethylmalonamide complexes of lanthanides. Comparison with the Americium complexC Den Auwer, M C Charbonnel, M G Drew, et al.
Cancer Chemotherapy and Pharmacology|February 4, 2014
Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trialCarlos R Becerra, Ramon Salazar, Rocio Garcia-Carbonero, et al.
World Journal of Gastroenterology|January 11, 2014
Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagusFergus Noble, Luke Nolan, Adrian C Bateman, et al.
British Journal of Cancer|June 9, 2026
Body mass index, adjuvant chemotherapy, toxicity, and survival in non-metastatic colorectal cancer: an individual participant data meta-analysis (OCTOPUS)Corinna G V Slawinski, Lee Malcomson, Jorge Barriuso, et al.
Wellcome Open Research|September 14, 2020
Using a knowledge exchange event to assess study participants' attitudes to research in a rapidly evolving research contextIona Beange, Elizabeth J Kirkham, Sue Fletcher-Watson, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|July 23, 2020
Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysisPhilip H Pucher, Saqib A Rahman, Robert C Walker, et al.
Pageof 58